Wim Robberecht
Overview
Explore the profile of Wim Robberecht including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
182
Citations
12415
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Opie-Martin S, Iacoangeli A, Topp S, Abel O, Mayl K, Mehta P, et al.
Nat Commun
. 2024 Jul;
15(1):5560.
PMID: 38956107
No abstract available.
2.
Chen Z, Reynolds R, Pardinas A, Gagliano Taliun S, van Rheenen W, Lin K, et al.
Neurobiol Dis
. 2023 Mar;
180:106082.
PMID: 36925053
Humans are thought to be more susceptible to neurodegeneration than equivalently-aged primates. It is not known whether this vulnerability is specific to anatomically-modern humans or shared with other hominids. The...
3.
Al Khleifat A, Iacoangeli A, Jones A, van Vugt J, Moisse M, Shatunov A, et al.
Front Cell Neurosci
. 2023 Jan;
16:1050596.
PMID: 36589292
Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the loss of upper and lower motor neurons, leading to progressive weakness of voluntary muscles, with death following from...
4.
The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration
Opie-Martin S, Iacoangeli A, Topp S, Abel O, Mayl K, Mehta P, et al.
Nat Commun
. 2022 Nov;
13(1):6901.
PMID: 36371497
Superoxide dismutase (SOD1) gene variants may cause amyotrophic lateral sclerosis, some of which are associated with a distinct phenotype. Most studies assess limited variants or sample sizes. In this international,...
5.
Al Khleifat A, Iacoangeli A, van Vugt J, Bowles H, Moisse M, Zwamborn R, et al.
NPJ Genom Med
. 2022 Jan;
7(1):8.
PMID: 35091648
There is a strong genetic contribution to Amyotrophic lateral sclerosis (ALS) risk, with heritability estimates of up to 60%. Both Mendelian and small effect variants have been identified, but in...
6.
Iacoangeli A, Fogh I, Selvackadunco S, Topp S, Shatunov A, van Rheenen W, et al.
Brain Commun
. 2021 Oct;
3(4):fcab236.
PMID: 34708205
Evidence indicates that common variants found in genome-wide association studies increase risk of disease through gene regulation via expression Quantitative Trait Loci. Using multiple genome-wide methods, we examined if Single...
7.
Johnson J, Miller D, Li R, Kumaran R, Alahmady N, Cookson M, et al.
JAMA Neurol
. 2021 Aug;
78(10):1236-1248.
PMID: 34459874
Importance: Juvenile amyotrophic lateral sclerosis (ALS) is a rare form of ALS characterized by age of symptom onset less than 25 years and a variable presentation. Objective: To identify the...
8.
Van Damme P, Tilkin P, Mercer K, Terryn J, DHondt A, Herne N, et al.
Brain Commun
. 2021 May;
2(2):fcaa160.
PMID: 33977260
We studied the feasibility, safety, tolerability and pharmacokinetics of intracerebroventricular delivery of recombinant human vascular endothelial growth factor in patients with amyotrophic lateral sclerosis. In this phase I study in...
9.
Van Damme P, Robberecht W
N Engl J Med
. 2021 Feb;
384(8):765-767.
PMID: 33626258
No abstract available.
10.
Eykens C, Rossaert E, Duque S, Rue L, Bento-Abreu A, Hersmus N, et al.
Mol Ther Methods Clin Dev
. 2021 Feb;
20:508-519.
PMID: 33614825
Oligodendrocyte dysfunction has been implicated in the pathophysiology of amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by progressive motor neuron loss. The failure of trophic support provided by oligodendrocytes...